- Home
- ARKO vs ABVX Comparison
ARKO vs ABVX Comparison
Compare ARKO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARKO
- ABVX
- Stock Information
- Founded
- ARKO 1970
- ABVX 2013
- Country
- ARKO United States
- ABVX France
- Employees
- ARKO N/A
- ABVX N/A
- Industry
- ARKO Oil Refining/Marketing
- ABVX
- Sector
- ARKO Energy
- ABVX
- Exchange
- ARKO Nasdaq
- ABVX Nasdaq
- Market Cap
- ARKO 501.4M
- ABVX 511.3M
- IPO Year
- ARKO N/A
- ABVX N/A
- Fundamental
- Price
- ARKO $4.66
- ABVX $66.49
- Analyst Decision
- ARKO Buy
- ABVX Buy
- Analyst Count
- ARKO 4
- ABVX 7
- Target Price
- ARKO $7.19
- ABVX $65.71
- AVG Volume (30 Days)
- ARKO 385.5K
- ABVX 2.8M
- Earning Date
- ARKO 08-06-2025
- ABVX 08-11-2025
- Dividend Yield
- ARKO 2.58%
- ABVX N/A
- EPS Growth
- ARKO N/A
- ABVX N/A
- EPS
- ARKO 0.03
- ABVX N/A
- Revenue
- ARKO $8,488,413,000.00
- ABVX $11,444,012.00
- Revenue This Year
- ARKO N/A
- ABVX $284.20
- Revenue Next Year
- ARKO N/A
- ABVX N/A
- P/E Ratio
- ARKO $179.09
- ABVX N/A
- Revenue Growth
- ARKO N/A
- ABVX 128.98
- 52 Week Low
- ARKO $3.51
- ABVX $4.77
- 52 Week High
- ARKO $7.84
- ABVX $72.90
- Technical
- Relative Strength Index (RSI)
- ARKO 56.65
- ABVX 92.92
- Support Level
- ARKO $4.53
- ABVX $9.96
- Resistance Level
- ARKO $4.73
- ABVX $72.90
- Average True Range (ATR)
- ARKO 0.15
- ABVX 1.84
- MACD
- ARKO 0.02
- ABVX 6.88
- Stochastic Oscillator
- ARKO 85.11
- ABVX 90.17
About ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.